Ahmed Bostamy Elsnhory

Ahmed Bostamy Elsnhory

Auto-generated profile, based on publicly available information

Ahmed Bostamy Elsnhory

Faculty of Medicine, Al-Azhar University, Cairo, Egypt

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2022 in Indian Heart Journal
Verified
Journal Article
Open access
FAFadel Alqatati
Fadel Alqatati
MEMohammad Elbahnasawy
Mohammad Elbahnasawy
SBSeif Bugazia
Seif Bugazia
KRKhaled Mohamed Ragab
Khaled Mohamed Ragab
AEAhmed Bostamy Elsnhory
Ahmed Bostamy Elsnhory
ANAnas Nourelden
Anas Nourelden
To assess the safety and efficacy of omecamtiv mecarbil compared with placebo in heart failure (HF) patients. We searched PubMed, Web of Science, Cochrane Library, and SCOPUS until August 15th, 2021. We included all randomized controlled studies comparing omecamtiv mecarbil with placebo in heart failure patients. The meta-analysis was carried out using Rev Man software V5.4. A total of eight studies were included in our systematic review. Pooled analysis showed that omecamtiv mecarbil is not associated with increased incidence of death, any adverse events, hypotension, heart failure, ventricular tachyarrhythmia, dyspnea, dizziness, and serious adverse events. Regarding the efficacy, omecamtiv mecarbil significantly reduced heart rate with some studies demonstrating its significant improvement in left ventricular ejection fraction and systolic function. Conclusion: Omecamtiv mecarbil is a well-tolerated drug in heart failure patients. The limited data regarding the efficacy suggested that it may improve ejection fraction and systolic function.

13 February 2026 in Indian Journal of Critical Care Medicine
Verified
Journal Article
Open access
MAMohammed A Alsabri
Mohammed A Alsabri
AEAhmed B Elsnhory
Ahmed B Elsnhory
MHMohammed T Hasan
Mohammed T Hasan
CMChristopher H McClean
Christopher H McClean
KAKhaled Abouelmagd
Khaled Abouelmagd
AHAysha Hasan
Aysha Hasan
Point-of-care ultrasonography (POCUS) is increasingly used to confirm endotracheal tube (ETT) placement; however, its overall diagnostic accuracy and speed compared with standard methods in adult emergency and critical care settings remain uncertain. We conducted a systematic review and meta-analysis of observational studies through May 2025 that evaluated POCUS for confirming ETT placement in adults (≥18 years) in emergency departments (EDs) and intensive care units (ICUs). Thirty studies met the inclusion criteria. Point-of-care ultrasonography achieved a pooled sensitivity of 0.91 and a specificity of 0.98. The area under the curve (AUC) was 0.96 [95% confidence interval (CI): 0.88–1.00]. The mean time-to-confirmation was 19.62 seconds for POCUS vs 22.46 seconds for standard methods; however, this finding should be interpreted with caution due to extreme heterogeneity (I² > 99%). Point-of-care ultrasonography is a highly accurate, rapid, and reliable method for confirming ETT placement in adult ED and ICU settings. It demonstrates diagnostic performance comparable to previously reported capnography performance and provides unique advantages as an adjunctive tool, especially in scenarios where capnography may be unreliable. Alsabri M, Elsnhory AB, Hasan MT, McClean CH, Abouelmagd K, Abady E, et al. Diagnostic Accuracy of Point-of-care Ultrasonography for Confirming Endotracheal Tube Placement in Adults: An Updated Systematic Review and Meta-analysis. Indian J Crit Care Med 2026;30(2):155–164.

21 November 2024 in Journal of Clinical and Experimental Hepatology
Verified
Journal Article
Closed access
MIMuhammad Imran
Muhammad Imran
AEAhmed B. Elsnhory
Ahmed B. Elsnhory
AIAhmed A. Ibrahim
Ahmed A. Ibrahim
MEMOHAMED B A Elnaggar
MOHAMED B A Elnaggar
MTMuhammad S. Tariq
Muhammad S. Tariq
MAMohamed Abuelazm
Mohamed Abuelazm

1 August 2023 in Current Women s Health Reviews
Verified
Journal Article
Closed access
PDF file
SBSeif Bugazia
Seif Bugazia
MBMohamed Boshnaf
Mohamed Boshnaf
MEMohammad Elbahnasawy
Mohammad Elbahnasawy
MSMostafa Shehata
Mostafa Shehata
FAFadel Alqatati
Fadel Alqatati
ANAnas Nourelden
Anas Nourelden
Background and objectives: Diabetes in pregnancy can lead to severe neonatal and maternal adverse events. Moreover, there is an increase in GDM prevalence. Therefore, we aimed to compare insulin detemir (IDet) with the neutral protamine Hagedorn (NPH) in diabetic pregnant women. Methods: We searched four electronic databases until August 2021: PubMed, Scopus, Web of Science, and Cochrane. We included randomized controlled studies that compared IDet with NPH in diabetic pregnant women. We extracted both maternal and neonatal outcomes, and used RevMan software to conduct the analysis. Results: A number of five studies were included. The analysis showed a significantly lower risk of hypoglycemic events during pregnancy in the IDet group than the NPH group [RR=0.6, 95% CI [0.43, 0.84], p=0.003], and a higher gestational age (GA) at delivery in the IDet group than the NPH group [MD= 0.28, 95% [0.02, 0.55], p=0.03]. On the other hand, the analysis revealed non-significant differences between IDet and NPH in terms of birth weight, congenital anomalies, neonatal hypoglycemia, preterm delivery, and others. Conclusion: Insulin detemir (IDet) was preferred over neutral protamine Hagedorn (NPH) in terms of showing lower rates of hypoglycemic events during pregnancy and a higher gestational age at delivery. Meanwhile, there were non-significant variations between them when it comes to neonatal outcomes, such as weight at birth, congenital anomalies, or neonatal hypoglycemia.

5 September 2022 in International Journal of Surgery
Verified
Journal Article
Closed access
Ramadan Abdelmoez FarahatRamadan Abdelmoez Farahat
Ramadan Abdelmoez Farahat
IAIftikhar Ali
Iftikhar Ali
AEAhmed Elsnhory
Ahmed Elsnhory
STSamar Tharwat
Samar Tharwat
Sirwan Khalid AhmedSirwan Khalid Ahmed
Sirwan Khalid Ahmed
EMEmery Manirambona
Emery Manirambona